Trade names Hepsera Routes of
administration Oral Molar mass 273.186 g/mol CAS ID 142340-99-6 | AHFS/Drugs.com Monograph ATC code J05AF08 (WHO) Bioavailability 59% | |
 | ||
Pregnancy
category AU: B3
US: C (Risk not ruled out) Legal status AU: S4 (Prescription only)
CA: ℞-only
UK: POM (Prescription only)
US: ℞-only | ||
Adefovir facts information about dosafe side effects of adefovir
Adefovir is a prescription medicine used to treat (chronic) infections with hepatitis B virus. A prodrug form of adefovir was previously called bis-POM PMEA, with trade names Preveon and Hepsera. It is an orally administered nucleotide analog reverse transcriptase inhibitor (ntRTI). It can be formulated as the pivoxil prodrug adefovir dipivoxil.
Contents
- Adefovir facts information about dosafe side effects of adefovir
- Adefovir medicine analysis research report
- Uses
- History
- Mechanism of action
- References
Adefovir medicine analysis research report
Uses
It is used for treatment of hepatitis B and herpes simplex virus infection.
Trials of adefovir in patients with HIV have not shown any clear benefits.
History
Adefovir was invented in the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic by Antonín Holý, and the drug was developed by Gilead Sciences for HIV with the brand name Preveon. However, in November 1999, an expert panel advised the U.S. Food and Drug Administration (FDA) not to approve the drug due to concerns about the severity and frequency of kidney toxicity when dosed at 60 or 120 mg. The FDA followed that advice, refusing to approve adefovir as a treatment for HIV.
Gilead Sciences discontinued its development for HIV treatment in December 1999, but continued to develop the drug for hepatitis B (HBV), where it is effective with a much lower dose of 10 mg. FDA approval for use in the treatment of hepatitis B was granted on September 20, 2002, and adefovir is sold for this indication under the brand name Hepsera. Adefovir became an approved treatment for HBV in the European Union in March 2003.
Mechanism of action
Adefovir works by blocking reverse transcriptase, an enzyme crucial for the HBV to reproduce in the body. It is approved for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (primarily ALT) or histologically active disease.
The main benefit of adefovir over lamivudine (the first NRTI approved for the treatment of HBV) is that it takes a much longer period of time for the virus to develop resistance to it.
Adefovir dipivoxil contains two pivaloyloxymethyl units, making it a prodrug form of adefovir.